Skip to main content
PELL BMT logo

PELL BMT — Investor Relations & Filings

Ticker · 6949 ISIN · TW0006949001 TW Professional, scientific and technical activities
Open in API
Filings indexed 23 across all filing types
Latest filing 2026-05-27 Investor Presentation
Country TW Taiwan
Listing TW 6949

About PELL BMT

https://www.pellbmt.com

Pell Biologics & Medical Technology Co., Ltd. specializes in the research, development, and clinical application of advanced cell and gene therapies. The company’s core expertise lies in Chimeric Antigen Receptor T-cell (CAR-T) therapy, adoptive T-cell therapy, and stem cell-based regenerative medicine. Its primary R&D pipeline includes CD19 CAR-T treatments for B-cell lymphoma, alongside Cytokine-Induced Killer (CIK) and Dendritic Cell-Cytokine Induced Killer (DC-CIK) immunotherapies. In the field of regenerative medicine, the company develops adipose-derived stem cell (ADSC) applications for degenerative arthritis and tissue repair. Operating within GTP and GMP-compliant facilities, the company focuses on critical technologies for cell isolation, activation, and expansion to deliver personalized precision medicine and high-quality cellular products.

Recent filings

Filing Released Lang Actions
115年05月法人說明會簡報 — 694920260527E001.pdf
Investor Presentation Classification · 90% confidence The document is a slide-based presentation with company overview, pipeline milestones, product development stages, clinical data, market analysis, and competitive positioning. It includes charts, tables, images, and structured slide numbers, indicating an investor-facing presentation rather than a regulatory filing or formal report. Therefore, it matches the definition of an Investor Presentation (IP).
2026-05-27 Chinese
115年05月法人說明會簡報 — 694920260527M001.pdf
Investor Presentation Classification · 91% confidence The document is a slide-based corporate presentation with company overview, 2026 milestones, pipeline details (CAR-T, PP011, PP021), clinical/pre-clinical data, market analysis, technology platforms, and core competencies. It reads as an investor pitch deck rather than an annual or interim report, earnings release, regulatory filing, or meeting announcement. It contains strategic and financial highlights aimed at potential investors. This matches the definition of an Investor Presentation (IP).
2026-05-27 Chinese
115年05月法人說明會簡報
Investor Presentation Classification · 80% confidence The document is a listing from Taiwan’s Market Observation Post System showing details of a corporate investor conference (“法人說明會”) including date, time, location, PDF links to Chinese/English presentation files, and video links. This is not a full financial report, earnings release, or management change notice, but rather an investor presentation event with associated slide materials. Therefore it best fits the Investor Presentation category.
2026-05-27 Chinese
本公司受邀參加台新證券舉辦之「台新2026年第二季全球投資論壇」
Regulatory Filings Classification · 75% confidence The document is a regulatory disclosure submitted to the Taiwan Market Observation Post System announcing the company’s invitation to participate in an upcoming investment forum (“法人說明會”) with date, time, and location details. It does not include any financial statements, report content, or officer certification, nor does it announce the publication of a report. It is an event notice without fitting other specific report categories, so it falls under the general Regulatory Filings (RNS) category.
2026-05-26 Chinese
115年05月法人說明會簡報
Investor Presentation Classification · 50% confidence The document is a schedule of "法人說明會" (institutional investor presentations) showing company code, meeting date, time, location, summary information, and links to presentation content. This is not AGM materials, an earnings release, or a regulatory delisting or insider-trading filing—it clearly relates to investor presentations. Although it’s an announcement rather than the slide deck itself, it falls under the Investor Presentation category.
2026-05-26 Chinese
公告本公司研發主管異動案
Board/Management Information Classification · 95% confidence The document is a formal announcement from a listed company (ticker 6949) regarding the resignation of the old R&D head and appointment of a new interim R&D head. This is clearly a senior management change notice under Regulated Information (Taiwanese Exchange filing). It is not a full report but an announcement of a management change, matching the Board/Management Information category.
2026-05-20 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.